Katherine R. Tuttle MD, FASN, FACP, FNKFExecutive Director for Research, Providence Health Care, Spokane, Washington; Professor of Medicine, Nephrology Division, University of Washington; Co-Principal Investigator, Institute of Translational Health Sciences, University of Washington, Seattle, Washington
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas.
Dr. Tuttle’s major research interests are in diabetes and chronic kidney disease. She has published over 250 original articles and served as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.
Dr. Tuttle is supported by four NIDDK/NIH grants, one NCATS/NIH grant, one NIMHD/NIH grant, and a CDC contract all from the US government. She has also received research grants to the institution from Goldfinch Bio, Bayer, and Travere.
Dr. Tuttle is a consultant on diabetes and CKD for Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk, and Bayer.